Merck & Company (MRK) 58.56 $MRK
Technical Data on Equities Reaching New highs -- Research on Banco Santander, Merck, Schlumberger, and Orbital Sciences
PR Newswire - 2 hrs 1 min ago
The U.S. stock markets on Tuesday, April 29, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,535.37, up 0.53% and the NASDAQ Composite closed at 4,103.54, up 0.72%. The S&P 500 finished the session 0.48% higher at 1,878.33. During the trading session, eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Banco Santander S.A. (NYSE: SAN), Merck & Co. Inc. (NYSE: MRK), Schlumberger Ltd (NYSE: SLB) and Orbital Sciences Corp. (NYSE: ORB). Free technical research on SAN, MRK, SLB and ORB can be downloaded upon signing up at:
The Dow Should Thank Merck, Caterpillar, and Johnson & Johnson for Its New Record
Dan Caplinger, The Motley Fool - Motley Fool - Wed Apr 30, 8:05PM CDT
On Wednesday, the Dow Jones Industrials set a new all-time record high, with its gain of 45 points just barely poking up into uncharted territory by about four points. Although there weren't really any stocks that stood out among the Dow's 30...
Merck
at Investor's Business Daily - Wed Apr 30, 5:53PM CDT
Merck (MRK) shares fell 0.3% to 58.56 after U.K. consumer-goods company Reckitt Benckiser said that it was no longer in talks to buy Merck's consumer-health arm.
Would Merck Be the Best Buyer for AstraZeneca?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Pfizer has already been rejected by AstraZeneca twice, but rumors suggest Pfizer may be considering another, higher bid for the company. While adding AstraZeneca's diabetes and oncology pipeline would bulk-up Pfizer nicely, Merck & Co. ...
Hospira Beats on Earnings & Sales, View Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:39PM CDT
Strong sales of SIP products led to the earnings beat at Hospira (HSP).
Big Pharma's Fall Slows the Dow's Momentum
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 30, 1:38PM CDT
The lack of surprises from today's Federal Open Market Committee meeting has the market on course for modest gains today, as the Dow Jones Industrial Average has gained about 30 points as of 2:30 p.m. EDT. However, most blue-chip members of the...
Earnings Round-up: Here's How Merck & Co Is Weathering Its Storm
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
Merck & Co hasn't had an easy go of it. Over the past few years, it's lost billions in sales as blockbuster drugs including Singulair have lost patent protection. As those sales have eroded, Merck has been slow to replace...
Why Reckitt Benckiser (RBGLY) Stock Is Lower
at The Street - Wed Apr 30, 12:38PM CDT
Shares of Reckitt Benckiser (RBGLY) are down after the company said it's no longer in active talks to buy the consumer health unit of Merck & Co. (MRK), although Bayer (BAYRY) has proposed a deal.
Jim Cramer: Spend Is a Four-Letter Word
at The Street - Wed Apr 30, 10:26AM CDT
The market wants companies that are taking share with minimal spending.
Global Non-Rhabdomyosarcoma Global Clinical Trials Review 2014
M2 - Wed Apr 30, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrg3gm/nonrhabdomyosarco) has announced the addition of the "Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" report to their offering. Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" provides data on the Non-Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Rhabdomyosarcoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - GlaxoSmithKline plc - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Zeltia, S.A. - Sarcoma Alliance for Research through Collaboration - Sanofi - Novartis AG - Merck & Co., Inc. - Amgen Inc. - National Cancer Institute - European Organization for Research and Treatment of Cancer - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Fred Hutchinson Cancer Research Center - Massachusetts General Hospital - Institut Bergonie - University of Michigan Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/mr...domyosarco
Julie Gerberding Receives AJC Women's Global Leadership Award
PR Newswire - Wed Apr 30, 9:47AM CDT
The American Jewish Committee (AJC) honored Dr. Julie L Gerberding, president of Merck Vaccines, with the global advocacy organization's Women's Global Leadership Award. The award was presented today at the AJC Women's Leadership Spring Luncheon, held at The Pierre Hotel in New York City.
FDA weighs over-the-counter approval of Singulair
By MATTHEW PERRONE - AP - Wed Apr 30, 9:45AM CDT
WASHINGTON (AP) — Federal health regulators are weighing the risks of permitting Merck to sell its prescription respiratory pill, Singulair, as an over-the-counter medicine for allergies.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Wed Apr 30, 5:31AM CDT
Merck KGaA (FRANKFURT: MRK)
Research and Markets: Global Osteoporosis Drugs Market Opportunities With Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate
Business Wire - Wed Apr 30, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vcjjsr/global) has announced the addition of the "Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate" report to their offering.
Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate
M2 - Wed Apr 30, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pzslm9/global) has announced the addition of the "Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate" report to their offering. There has been an increase in awareness of bone education among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of osteoporosis drugs is expected to rise due to the increasing public awareness. This will probably result in increasing drug penetration. Raising general awareness about osteoporosis has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as National Osteoporosis Awareness and Prevention Month every year. This has encouraged women and men to start conversations about bone health and family history as the first steps to protecting themselves and future generations from osteoporosis. Similarly, the National Osteoporosis Foundation is the leading health organization dedicated to preventing osteoporosis and broken bones, promoting strong bones for life, and reducing human suffering, through programs of public and clinician awareness, education, advocacy, and research. These collaborations have helped to considerably increase the awareness about osteoporosis drugs. According to the report, one of the main drivers in this market is the increase in the global aging population. The number of patients suffering from osteoporosis is increasing owing to the increasing aging population both in developing and developed nations. The prevalence of osteoporosis and the incidence of osteoporotic fractures rise substantially with age, especially after the age of 50 years. Further, the report states that one of the main challenges is the multiple patent expiries. The shift toward lower-priced drugs will lead to a drop in the market valuations for that drug, reducing the overall market value. Key vendors dominating this space are: - Amgen Inc - Eli Lilly & Co - Merck & Co. Inc. - Novartis AG. Other vendors mentioned in the report are: - Abiogen Pharma SpA - F. Hoffmann La Roche Ltd. - GlaxoSmithKline plc - Ligand Pharmaceuticals Inc. - NPS Pharma Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pzslm9/global
Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management
PRWeb - Wed Apr 30, 2:25AM CDT
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Chemical Development Summit, held April 23 - 24, 2014 at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. The meeting featured a tour of the BMS high throughput lab, customer case studies, and discussions of best practices in high throughput research and data management.
Why Twitter and eBay Stumbled After Hours
Jeremy Bowman, The Motley Fool - Motley Fool - Tue Apr 29, 9:36PM CDT
Stocks pushed higher again today on strong earnings reports from big names including Merck , and momentum stocks that had fallen over the past few days bounced back. By the end of the day, the Dow Jones Industrial Average finished up 87 points,...
Technical Data on Equities Reaching New highs -- Research on Banco Santander, Merck, Schlumberger, and Orbital Sciences
PR Newswire - 2 hrs 1 min ago
The U.S. stock markets on Tuesday, April 29, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,535.37, up 0.53% and the NASDAQ Composite closed at 4,103.54, up 0.72%. The S&P 500 finished the session 0.48% higher at 1,878.33. During the trading session, eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Banco Santander S.A. (NYSE: SAN), Merck & Co. Inc. (NYSE: MRK), Schlumberger Ltd (NYSE: SLB) and Orbital Sciences Corp. (NYSE: ORB). Free technical research on SAN, MRK, SLB and ORB can be downloaded upon signing up at:
The Dow Should Thank Merck, Caterpillar, and Johnson & Johnson for Its New Record
Dan Caplinger, The Motley Fool - Motley Fool - Wed Apr 30, 8:05PM CDT
On Wednesday, the Dow Jones Industrials set a new all-time record high, with its gain of 45 points just barely poking up into uncharted territory by about four points. Although there weren't really any stocks that stood out among the Dow's 30...
Merck
at Investor's Business Daily - Wed Apr 30, 5:53PM CDT
Merck (MRK) shares fell 0.3% to 58.56 after U.K. consumer-goods company Reckitt Benckiser said that it was no longer in talks to buy Merck's consumer-health arm.
Would Merck Be the Best Buyer for AstraZeneca?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Pfizer has already been rejected by AstraZeneca twice, but rumors suggest Pfizer may be considering another, higher bid for the company. While adding AstraZeneca's diabetes and oncology pipeline would bulk-up Pfizer nicely, Merck & Co. ...
Hospira Beats on Earnings & Sales, View Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:39PM CDT
Strong sales of SIP products led to the earnings beat at Hospira (HSP).
Big Pharma's Fall Slows the Dow's Momentum
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 30, 1:38PM CDT
The lack of surprises from today's Federal Open Market Committee meeting has the market on course for modest gains today, as the Dow Jones Industrial Average has gained about 30 points as of 2:30 p.m. EDT. However, most blue-chip members of the...
Earnings Round-up: Here's How Merck & Co Is Weathering Its Storm
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
Merck & Co hasn't had an easy go of it. Over the past few years, it's lost billions in sales as blockbuster drugs including Singulair have lost patent protection. As those sales have eroded, Merck has been slow to replace...
Why Reckitt Benckiser (RBGLY) Stock Is Lower
at The Street - Wed Apr 30, 12:38PM CDT
Shares of Reckitt Benckiser (RBGLY) are down after the company said it's no longer in active talks to buy the consumer health unit of Merck & Co. (MRK), although Bayer (BAYRY) has proposed a deal.
Jim Cramer: Spend Is a Four-Letter Word
at The Street - Wed Apr 30, 10:26AM CDT
The market wants companies that are taking share with minimal spending.
Global Non-Rhabdomyosarcoma Global Clinical Trials Review 2014
M2 - Wed Apr 30, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrg3gm/nonrhabdomyosarco) has announced the addition of the "Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" report to their offering. Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" provides data on the Non-Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Rhabdomyosarcoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - GlaxoSmithKline plc - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Zeltia, S.A. - Sarcoma Alliance for Research through Collaboration - Sanofi - Novartis AG - Merck & Co., Inc. - Amgen Inc. - National Cancer Institute - European Organization for Research and Treatment of Cancer - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Fred Hutchinson Cancer Research Center - Massachusetts General Hospital - Institut Bergonie - University of Michigan Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/mr...domyosarco
Julie Gerberding Receives AJC Women's Global Leadership Award
PR Newswire - Wed Apr 30, 9:47AM CDT
The American Jewish Committee (AJC) honored Dr. Julie L Gerberding, president of Merck Vaccines, with the global advocacy organization's Women's Global Leadership Award. The award was presented today at the AJC Women's Leadership Spring Luncheon, held at The Pierre Hotel in New York City.
FDA weighs over-the-counter approval of Singulair
By MATTHEW PERRONE - AP - Wed Apr 30, 9:45AM CDT
WASHINGTON (AP) — Federal health regulators are weighing the risks of permitting Merck to sell its prescription respiratory pill, Singulair, as an over-the-counter medicine for allergies.
Stock Market News for April 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 9:06AM CDT
Upbeat earnings results and gains in high-growth stocks helped benchmarks close in the green on Tuesday
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Wed Apr 30, 5:31AM CDT
Merck KGaA (FRANKFURT: MRK)
Research and Markets: Global Osteoporosis Drugs Market Opportunities With Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate
Business Wire - Wed Apr 30, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vcjjsr/global) has announced the addition of the "Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate" report to their offering.
Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate
M2 - Wed Apr 30, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pzslm9/global) has announced the addition of the "Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate" report to their offering. There has been an increase in awareness of bone education among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of osteoporosis drugs is expected to rise due to the increasing public awareness. This will probably result in increasing drug penetration. Raising general awareness about osteoporosis has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as National Osteoporosis Awareness and Prevention Month every year. This has encouraged women and men to start conversations about bone health and family history as the first steps to protecting themselves and future generations from osteoporosis. Similarly, the National Osteoporosis Foundation is the leading health organization dedicated to preventing osteoporosis and broken bones, promoting strong bones for life, and reducing human suffering, through programs of public and clinician awareness, education, advocacy, and research. These collaborations have helped to considerably increase the awareness about osteoporosis drugs. According to the report, one of the main drivers in this market is the increase in the global aging population. The number of patients suffering from osteoporosis is increasing owing to the increasing aging population both in developing and developed nations. The prevalence of osteoporosis and the incidence of osteoporotic fractures rise substantially with age, especially after the age of 50 years. Further, the report states that one of the main challenges is the multiple patent expiries. The shift toward lower-priced drugs will lead to a drop in the market valuations for that drug, reducing the overall market value. Key vendors dominating this space are: - Amgen Inc - Eli Lilly & Co - Merck & Co. Inc. - Novartis AG. Other vendors mentioned in the report are: - Abiogen Pharma SpA - F. Hoffmann La Roche Ltd. - GlaxoSmithKline plc - Ligand Pharmaceuticals Inc. - NPS Pharma Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pzslm9/global
Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management
PRWeb - Wed Apr 30, 2:25AM CDT
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Chemical Development Summit, held April 23 - 24, 2014 at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. The meeting featured a tour of the BMS high throughput lab, customer case studies, and discussions of best practices in high throughput research and data management.
Why Twitter and eBay Stumbled After Hours
Jeremy Bowman, The Motley Fool - Motley Fool - Tue Apr 29, 9:36PM CDT
Stocks pushed higher again today on strong earnings reports from big names including Merck , and momentum stocks that had fallen over the past few days bounced back. By the end of the day, the Dow Jones Industrial Average finished up 87 points,...
